Table 2.
Patient characteristics in the first supplementary analysis
| SABR | CFRT | |||||
|---|---|---|---|---|---|---|
| Standardized difference (rounded)* | ||||||
| Number or mean (sd)* | (%)* | Number or mean (sd)* | (%)* | |||
| Age | 77.47 (8.26) | 77.75 (9.79) | 0.03 | |||
| Sex | Female | 18 | (30) | 24 | (40) | 0.21 |
| Male | 42 | (70) | 36 | (60) | ||
| Residency | Non-north | 29 | (48) | 30 | (50) | 0.03 |
| North | 31 | (52) | 30 | (50) | ||
| Comorbidity | Without | 9 | (15) | 8 | (13) | 0.05 |
| With† | 51 | (85) | 52 | (87) | ||
| Histology | Adenocarcinoma | 37 | (62) | 41 | (68) | 0.14 |
| Non-adenocarcinoma | 23 | (38) | 19 | (32) | ||
| T stage | T1 | 30 | (50) | 31 | (52) | 0.03 |
| T2 | 30 | (50) | 29 | (48) | ||
| Period | 2007–2009 | 15 | (25) | 15 | (25) | 0.00 |
| 2010–2013 | 45 | (75) | 45 | (75) | ||
| Use of PET | Yes | 30 | (50) | 31 | (52) | 0.03 |
| No | 30 | (50) | 29 | (48) | ||
| Use of systemic therapy | Yes | 10 | (17) | 13 | (22) | 0.13 |
| No | 50 | (83) | 47 | (78) | ||
| Previous cancer | Yes | 8 | (13) | 7 | (12) | 0.05 |
| No | 52 | (87) | 53 | (88) | ||
CFRT = conventional fractionated radiotherapy; PET = positron emission tomography; SABR = stereotactic ablative radiotherapy; sd = standard deviation;
*
rounded at the second
†
modified Carlson comorbidity score ≥ 1